Close

Deutsche Bank (RGLS) Maintains Buy on Regulus Therapeutics (RGLS)

February 9, 2015 10:35 AM EST Send to a Friend
Deutsche Bank maintained a Buy rating on Regulus Therapeutics (NASDAQ: RGLS) with a price target of $30. Analyst Alethia Young ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login